Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL), reinforcing its commitment to biopharmaceutical innovation. This partnership aims to enhance continuous manufacturing solutions, improve supply chain logistics, and increase accessibility to biotherapeutics. CEO Mike McMullen emphasized the growing importance of innovative measurement tools for delivering life-saving drugs. Agilent's advanced technologies, such as online HPLC sampling and real-time sensors, will play a vital role in shaping future bioprocess development.
- Agilent's membership in NIIMBL highlights its dedication to biomanufacturing innovation.
- Focus on continuous manufacturing can improve supply chain logistics and patient access.
- Agilent offers advanced technologies that address critical needs in biopharmaceuticals.
- None.
Support for biologics manufacturability and Industry 4.0 initiatives
The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufacturing footprint and improve supply chain logistics and biotherapeutic access by enabling manufacturing to move closer to patients, especially in underserved areas. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, which will fundamentally advance
“Agilent has long played a key role in providing trusted answers for the analytical needs of the biopharmaceutical industry,” said Agilent CEO
Agilent’s online HPLC sampling portfolio, cellular imaging, and real-time sensor technologies exemplify how the company can help address current and emerging needs. Additionally, Agilent’s NIIMBL membership will allow us to work closely with all continuum partners to help shape the future of innovation and standards used in bioprocess development and biomanufacturing.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005201/en/
+1.781.266.2819
naomi.goumillout@agilent.com
Source:
FAQ
What is Agilent Technologies' recent partnership in biomanufacturing?
How does Agilent's membership in NIIMBL benefit the biomanufacturing industry?
What technologies is Agilent using to support biopharmaceutical manufacturing?